Prevalence and predictors of clinically significant statin-drug interactions among Yemeni patients taking statins for primary and secondary prevention of cardiovascular disease.
Fahmi Y Al-AshwalSyed Azhar Syed SulaimanSiti Maisharah Sheikh GhadziMohammed Abdullah KubasAbdulsalam M HalboupPublished in: Current medical research and opinion (2022)
Patients with polypharmacy and those with three or more comorbidities had a higher risk for statin-drug interactions. Therefore, routine screening by physicians and pharmacists for potential interactions should occur before prescribing or dispensing any medication to avoid clinically significant statin-drug interactions.
Keyphrases
- cardiovascular disease
- primary care
- end stage renal disease
- coronary artery disease
- ejection fraction
- newly diagnosed
- adverse drug
- type diabetes
- chronic kidney disease
- risk factors
- healthcare
- cardiovascular risk factors
- peritoneal dialysis
- emergency department
- prognostic factors
- low density lipoprotein
- patient reported outcomes
- risk assessment
- general practice
- patient reported